COMPANY FACT FILE THE COMPANY VISION
The overall company vision for Covidien is to create and deliver innovative healthcare solutions, developed in ethical collaboration with medical professionals, which enhance quality of life for patients and improve outcomes for customers. Covidien is focused on becoming a leading global healthcare product company through innovation. By creating innovative medical solutions, the company will help improve patient outcomes and deliver value through clinical leadership and excellence. They plan to achieve this via:
n Focus on growth n Commitment to innovation n Leveraging global structure n Driving operational excellence n Increased portfolio management.
Covidien has a major focus on research and development,
with nearly $450 million spent on research and development in 2010, with that amount expected to increase in 2011. It also seeks to expand its portfolio via acquisition. Covidien stock[17] quoted on the New York Stock Exchange (NYSE).
Recent technical innovations developed by the company include: n KendallTM
AMD foam dressings: antimicrobial dressings
utilising AMD technology containing 0.2-0.5% PHMB to prevent wound infection
n KendallTM DL disposable cable and lead wire system:
designed to address patient safety and comfort, electrical performance and ease of use
n AbsorbaTackTM repair
n V-LocTM absorbable mesh fixation device for hernia absorbable wound closure device: a self-anchoring
loop and barb combination, which enables wound closure without the need to tie knots; it permits simultaneous closure of multiple dermal layers
n DuraSealTM spine sealant: a hydrogel-based product used to
repair dural tears; the first product approved by the US Food and Drug Administration for intra-operative sealing of the dural membrane during spinal procedures
n SILSTM Port: a multiple instrument/single-incision access port used in laparoscopic surgery
n Mallinckrodt™ TaperGuard™ and TaperGuard™ Evac endotracheal tubes designed to minimise risk of microaspiration in intubated patients.
is Covidien and the future for wound care
In line with the company’s vision for long-term growth, Covidien plans to maintain and expand its wide range of traditional and advanced wound care products and equipment, with research into, and acquisition of, new products and technologies. Key areas in which the company expects to focus in future include antimicrobial dressing technology to reduce the risk of wound infection, utilising polyhexamethylene biguanide (polihexanide, PHMB), and ongoing support for education in wound care.
LINKS/REFERENCES 1.
http://www.covidien.com/covidien/pages.
aspx?page=Home
2 .
www.kendallhealthcare.com/ kendallhealthcarepagebuilder.aspx?webPageID=121555
3.
http://www.autosuture.com/autosuture/pagebuilder.as px?webPageID=63662&websiteID=63656
4.
http://www.covidien.com/covidien/pages. aspx?page=Brands/BioSurgery”
http://www.covidien. com/covidien/
pages.aspx?page=Brands/BioSurgery
5.
http://www.covidien.com/campaigns/pagebuilder.aspx ?topicID=121347&page=Indermil:Main
6.
http://www.covidien.com/cavitating/pages. aspx?page=Brands/Devon
7.
http://www.valleylab.com 8.
http://www.covidien.com/covidien/pages. aspx?page=Brands/Mallinckrodt
9.
http://respiratorysolutions.covidien.com 10
http://www.covidien.com/covidien/ featherbeddings=Education/Centers
11.
http://covidien.mhsoftware.com 12
http://www.covidien.com/covidien/pages. aspx?page=Education/AdvancedTraining
13.
http://www.surgicalfellowships.org 14.
http://www.flsprogram.org 15. Leaper D. Technology update: the role of PHMB in delayed wound healing.Wounds International 2010:1(5).
http://www.woundsinternational.com/article.php?conte ntid=129&articleid=8922&page=2
16. Gaertner W. Bonsak
M.Delaney J. Experimental Evaluation of four Biologic prostheses for Ventral hernia repair. Journal of Gastrointestinal Surgery, 2007.
17.
http://investor.covidien.com/phoenix. zhtml?c=207592&p=irol-alerts
This article has been supported by an educational grant from Covidien
The views expressed in this article do not necessarily reflect those of Covidien For further information about Covidien please visit:
www.covidien.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61